euro adhoc: Intercell AG / other / Intercell granted Early Termination of HSR Waiting Period for Iomai-Acquisition

--------------------------------------------------------------------------------
Disclosure announcement transmitted by euro adhoc. The issuer is responsible
for the content of this announcement.
--------------------------------------------------------------------------------

Company Information

05.06.2008

Vienna (Austria), June 5, 2008 - Intercell AG (VSE: ICLL) today
announced that it has received notice that the U.S. Department of
Justice and Federal Trade Commission have granted early termination
of the waiting period under the Hart-Scott-Rodino Antitrust
Improvements Act of 1976, as amended, for Intercell AG´s proposed
acquisition of Iomai Corporation.

As previously announced, Iomai and Intercell AG have entered into an
Agreement and Plan of Merger (the "Merger Agreement") whereby Iomai
has agreed to be acquired by Intercell AG subject to the terms and
conditions of the Merger Agreement. The transaction still requires
the approval of Iomai stockholders and clearance by the Committee on
Foreign Investment in the United States, and is subject to other
closing conditions.

Under the terms of the proposed acquisition, Intercell will acquire
Iomai for USD 6.60 per share of Iomai´s common stock representing a
fully diluted equity value of Iomai of approximately USD 189 million
(EUR 122 million). The consideration will be paid in cash and stock.
Iomai´s public shareholders, representing approximately 59 percent of
Iomai´s outstanding common stock will receive cash. Certain of
Iomai´s largest shareholders, together representing approximately 41
percent of Iomai´s outstanding common stock, have agreed to exchange
their shares for Intercell stock at an exchange ratio corresponding
to a value of USD 6.60 per share of Iomai common stock upon closing.

The combination is structured as a share exchange together with a
merger of Iomai and a US subsidiary of Intercell. Certain of Iomai´s
largest shareholders (and their affiliates), which together represent
over 50 percent of Iomai´s outstanding common stock, have agreed
pursuant to a voting agreement with Intercell that they will vote
their shares in favour of the merger.

Important Additional Information Regarding the Transaction

In connection with the proposed transaction, on May 14, 2008, Iomai
Corporation filed a preliminary proxy statement for its stockholders
with the Securities and Exchange Commission (SEC). Iomai Corporation
will be filing a definitive proxy statement for its stockholders and
other documents regarding the proposed transaction with the SEC.
BEFORE MAKING ANY VOTING OR INVESTMENT DECISION, IOMAI STOCKHOLDERS
AND INVESTORS ARE URGED TO CAREFULLY READ THE PRELIMINARY PROXY
STATEMENT AND, WHEN IT BECOMES AVAILABLE, THE DEFINITIVE PROXY
STATEMENT AS WELL AS ANY OTHER RELEVANT MATERIALS, IN THEIR ENTIRETY
BECAUSE THE DOCUMENTS WILL CONTAIN IMPORTANT INFORMATION ABOUT THE
PROPOSED TRANSACTION AND IOMAI. Investors and stockholders may obtain
copies of the proxy statements and other relevant documents filed
with the SEC by Iomai free of charge at the SEC´s web site at
www.sec.gov. In addition, investors and stockholders may obtain
copies of the proxy statements and other relevant documents filed
with the SEC by Iomai free of charge (when they are available) by
going to Iomai´s Investor Relations page on its corporate website at
www.iomai.com.

Iomai and its directors, executive officers and other members of
management may be deemed to be participants in the solicitation of
proxies from Iomai's stockholders with respect to the proposed
transaction. Information regarding the interests of such potential
participants in the proxy solicitation are contained in the
preliminary proxy statement and will be contained in the definitive
proxy statement and other relevant materials to be filed with the SEC
when they become available.

About Iomai Corporation

Iomai Corporation has approximately 110 employees and discovers and
develops vaccines and immune system stimulants, delivered via a
novel, needle-free technology called transcutaneous immunization
(TCI). TCI, discovered by researchers at the Walter Reed Army
Institute of Research, taps into the unique benefits of a major group
of antigen-presenting cells found in the outer layers of the skin to
generate an enhanced immune response. Iomai is leveraging TCI to
enhance the efficacy of existing vaccines, develop new vaccines that
are viable only through transcutaneous administration and expand the
global vaccine market. Iomai currently has four product candidates
in development: one to prevent traveller´s diarrhea and three
targeting influenza and pandemic flu. Iomai is listed on the NASDAQ
Global Market under the symbol "IOMI".

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Intercell AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Intercell AG

Lucia Malfent

Head of Communications

Tel. +43 1 20620-303

lmalfent@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Index: ATX Prime, ATX
Börsen: Wiener Börse AG / official market